Core Viewpoint - Company is facing challenges in the in vitro diagnostic (IVD) industry due to intensified competition and demand pressure, leading to a decline in revenue and profit in the first half of 2025 [2][10]. Group 1: Financial Performance - In the first half of 2025, the company achieved revenue of 1.246 billion yuan, a year-on-year decrease of 20.92%, and a net profit attributable to shareholders of 189 million yuan, down 46.82% [10]. - The second quarter of 2025 saw a single-quarter revenue of 445 million yuan, a decline of 37.64%, and a net profit of only 6.35 thousand yuan, down 99.95% [10]. - The company's accounts receivable at the end of the first half of 2025 stood at 1.19 billion yuan, slightly up from 1.12 billion yuan at the beginning of the year but down 12.5% from 1.36 billion yuan at the end of the first quarter [4]. Group 2: Business Strategy and Development - The company is focusing on IPD transformation to strengthen core competitiveness and is committed to innovation in the immunology field while expanding its technical capabilities [2]. - The company is implementing a strategy of "combination, internationalization, and digitalization" to become a globally trusted IVD enterprise [4]. - The international department has expanded its operations to over 150 countries and regions, with a focus on local operations and increasing the proportion of local employees [4][5]. Group 3: Product Development and Market Expansion - In the infectious disease testing sector, the company is enhancing the coverage of flu testing products and pushing for the introduction of new respiratory disease detection products [3]. - The company has launched the Ucare-6000 fully automated blood gas and biochemical analyzer in the domestic market, providing cost-effective solutions for hospitals [3]. - The company is also focusing on the North American toxicology testing market, achieving significant sales on platforms like Amazon [3][7]. Group 4: Future Outlook - The company anticipates a stable development in its fluorescence business and aims to enhance its product offerings in grassroots medical institutions [8]. - The international department's performance in the first half of 2025 has laid a solid foundation for achieving annual performance targets [9]. - The company is committed to addressing external pressures through strategic adjustments and is optimistic about opportunities in international markets, particularly in the "Belt and Road" regions and the U.S. market [9].

Investment Rating - The report maintains a "Buy" rating for the company [7] Core Views - The company achieved revenue of 1.246 billion RMB in 1H25, a year-on-year decrease of 20.9%, and a net profit attributable to the parent company of 189 million RMB, down 46.8% year-on-year, primarily due to domestic policy changes affecting hospital demand and a weaker outbreak of respiratory infectious diseases compared to the same period in 2024 [1][3] - Despite short-term challenges, the company is expected to maintain long-term growth potential due to its expanding product portfolio and improving domestic and international sales networks [1][3] Summary by Sections Revenue and Profitability - The company's gross margin in 1H25 was 62.9%, a decrease of 1.5 percentage points year-on-year, attributed to domestic policy changes impacting product pricing [2] - The sales, management, and R&D expense ratios for 1H25 were 25.6%, 7.3%, and 14.0%, respectively, with increases of 5.4, 0.5, and 1.5 percentage points year-on-year, indicating ongoing investment in commercialization and R&D [2] Business Segments - The U.S. subsidiary's revenue in 1H25 is estimated to have grown nearly 20%, supported by stable toxicology testing and new respiratory testing products [3] - The international department's revenue is expected to show steady growth due to ongoing localization efforts and the introduction of new products [3] - Domestic business revenue is projected to decline in 1H25 due to external environmental factors, but long-term growth is anticipated through strategic advancements in immunofluorescence and other key areas [3] Long-term Business Outlook - Infectious disease testing revenue was 379 million RMB, down 21.1% year-on-year, primarily due to lower outbreak intensity [4] - Chronic disease testing revenue was 563 million RMB, down 26.1% year-on-year, affected by policy changes [4] - Toxicology and prenatal testing revenues were 145 million RMB and 138 million RMB, showing growth of 4.3% and a decline of 11.7% respectively, with expectations for improvement through new product launches and e-commerce channel development [4] Profit Forecast and Valuation - The report adjusts the profit forecast for 2025-2027, estimating net profits of 426 million RMB, 491 million RMB, and 582 million RMB, reflecting downward adjustments of 35% for 2025 and 2026, and 33% for 2027 [5][13] - The company is valued at a 34x PE for 2025, with a target price of 30.09 RMB, up from a previous estimate of 27.07 RMB [5][8]